Harnessing bispecific nanobodies
Innovative Myeloma Solutions
Immune-based therapies are transforming the care of people with myeloma. While current treatments work well, many patients experience disease recurrance and need a different way of directing their immune system. We are developing first-in-class immunotherapies using specialized antibodies naturally found in camelids like llamas. Our proprietary small and effective "nanobodies" have 2 or more arms, bringing T lymphocytes or natural killer cells to malignant plasma cells. Our proprietary nanobodies recognize the marker TACI on the surface of myeloma cells, rather than the more commonly target, BCMA. Individuals who need more treatment before or after current immune agents like ciltacebtagene autoleucel, idecabtagene vicleucel, teclistimab or elranatamab will now have more options.
Myeloma is a word, not a sentence.
Our Science: TACI is a member of the TNF Superfamily of B lymphocyte regulators. Targetting it removes mature plasma cells.
myellama therapeutics is developing a family of proprietary TACI-based cell and multispecific nanobodies
TACI immuntherapies are effective
We have developed a family of TACI nanobody-based therapies which are effective when deployed as chimeric antigen receptors in T lymphocytes (CART), T Cell Engagers (TCE) and as bispecific NK Cell Engagers (BiKE). This class of immunotherapy complements existing B Cell Maturation Antigen (BCMA) immunotherapeutics and provides a good option for patients with persistant/relapsing disease.
Meet the team
Scott McComb PhD
Scientific Advisory Board Chair
Brent Zanke MD PhD
CEO
Alissa Visrama MSc MD
Medical Advisory Board Chair
Dr. McComb is a pioneer in the therapeutic use of nanobodies. He has identified new approaches to their deployment in myeloma therapy.
Dr. Zanke, a medical oncologist and entrepreneur knows that scientific innovation needs creative development to unlock value and societal benefit.
Dr. Visrama, a recognized myeloma clinical expert has thoughtful and innovative approaches to the development of new therapies.
myellama therapeutics is fund raising
We are a pre-clinical company advancing our lead TACI product, a bispecific NK Cell Engager to clinical testing in late 2025. We are raising development capital.
For detailed information on our approach, our team and proprietary assets please contact bzanke@myellama.com